Exactly Chimp. You can’t present the same data at different...

Exactly Chimp. You can’t present the same data at different conferences anyway. This maybe the reason for the hold up on Janssen data AND FDA.

I’m excited about this. RenalytixAI are presenting at ADA also...cost of their AI based test US$900 plus. PIQ US$55-150. Look at RenalytixAI & their cash burn & MC. Look at revenue from their test, $100k, roughly 100 tests. Anyone see something wrong with this? They got a Govt contract, Breakthrough Device Designation, it’s predictive in patients ALREADY suffering DKD & progression, but NOT Prognostic.

Look at PIQ...I think our revenue has topped RenalytixAI for analytics (other) & helping to fund R&D and staff costs. PROGNOSTIC test for DKD up to 4 years prior to abnormalities found in current pathology tests (KDIGO Guidelines International Gold Standard for CKD/DKD now, so we should see some comparison/reference to this).

Also PREDICTIVE of Renal decline for patients with DKD, both on Canagliflozin (Invokana) & Placebo in a large validation study >3000 patients on CANVAS Study (cardio-renal) in Ph1 with PromarkerD. Validated & Janssen included this study on their Prescriber Information. These data were presented in 2019 at ADA Conference in the USA (co-presentation with Janssen & PIQ). This then resulted in a Ph2 of PromarkerD collaboration. The lab analysis was completed some time ago.

We await.